Stocklytics Platform
Asset logo for symbol YMAB
Y-mAbs Therapeutics
YMAB64
$5.16arrow_drop_down1.61%-$0.08
Asset logo for symbol YMAB
YMAB64

$5.16

arrow_drop_down1.61%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Y-mAbs Therapeutics (YMAB) Stocklytics Forecast

Y-mAbs Therapeutics Inc (YMAB) is a biopharmaceutical company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. The company's mission is to improve outcomes for patients with cancer by developing targeted therapies that address significant unmet medical needs. YMAB's pipeline consists of a diverse portfolio of antibody products, targeting various cancer indications and utilizing different mechanisms of action. The company's lead product candidate, naxitamab, is currently under review by the FDA for the treatment of high-risk neuroblastoma.
Looking ahead, there is significant potential for YMAB's stock price to experience growth. The company's pipeline is robust, with multiple product candidates in various stages of development. If approved, these products could generate significant revenue for YMAB and drive its stock price higher. Moreover, the company has a strong track record of advancing its pipeline and successfully bringing products to market. This track record instills confidence in YMAB's ability to execute its business strategy and achieve its goals.
add Y-mAbs Therapeutics  to watchlist

Keep an eye on Y-mAbs Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Y-mAbs Therapeutics (YMAB) stock?

Analysts have set a target price of $16.04 for Y-mAbs Therapeutics (YMAB), based on forecasts from 23 analysts. The predicted price range extends from a high of $63 to a low of $5. This represents a potential increase of up to 1.12K% and a decrease of -3.1% from the current price of $5.16. These forecasts are as of 2022 Jan 03.
help

What are the analyst ratings for Y-mAbs Therapeutics (YMAB) stock?

Currently, there are no analyst ratings available for Y-mAbs Therapeutics (YMAB), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Y-mAbs Therapeutics (YMAB) stock?

At present, there is no AI or machine-learning-based price prediction available for Y-mAbs Therapeutics (YMAB) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level